Allogene Therapeutics shares fall 1.36% intraday after Sumitomo Pharma and RACTHERA submit application for Parkinson's disease treatment.

Allogene Therapeutics, Inc. declined 1.36% in intraday trading. The company's stock price movement may be influenced by the recent news events related to Sumitomo Pharma Co., Ltd. and its subsidiaries, which are involved in the development and manufacturing of regenerative medicine and cell therapy products. The news events include the submission of an application for manufacturing and marketing authorization for allogeneic iPS cell-derived dopaminergic neural progenitor cells, the expansion of production capacity for regenerative medicine and cell therapy, and the completion of a new manufacturing facility. These events may have a positive impact on the company's future growth and development, but the stock price movement suggests that investors may be cautious or uncertain about the company's prospects.